Join Growin Stock Community!

Zai lab limitedZLAB.US Overview

US StockHealthcare
(No presentation for ZLAB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZLAB AI Insights

ZLAB Overall Performance

ZLAB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZLAB Recent Performance

-4.23%

Zai lab limited

0.05%

Avg of Sector

-0.31%

S&P500

ZLAB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZLAB Key Information

ZLAB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZLAB Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Price of ZLAB

ZLAB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZLAB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.59
PE Ratio (TTM)
-
Forward PE
32.44
PS Ratio (TTM)
4.68
PB Ratio
2.84
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
58.47%
Net Margin
-38.15%
Revenue Growth (YoY)
15.33%
Profit Growth (YoY)
7.15%
3-Year Revenue Growth
26.79%
3-Year Profit Growth
16.13%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.59
PE Ratio (TTM)
-
Forward PE
32.44
PS Ratio (TTM)
4.68
PB Ratio
2.84
Price-to-FCF
-
Gross Margin
58.47%
Net Margin
-38.15%
Revenue Growth (YoY)
15.33%
Profit Growth (YoY)
7.15%
3-Year Revenue Growth
26.79%
3-Year Profit Growth
16.13%

  • When is ZLAB's latest earnings report released?

    The most recent financial report for Zai lab limited (ZLAB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZLAB's short-term business performance and financial health. For the latest updates on ZLAB's earnings releases, visit this page regularly.

  • What is the operating profit of ZLAB?

    According to the latest financial report, Zai lab limited (ZLAB) reported an Operating Profit of -68.91M with an Operating Margin of -54.01% this period, representing a decline of 3.7% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ZLAB's revenue growth?

    In the latest financial report, Zai lab limited (ZLAB) announced revenue of 127.6M, with a Year-Over-Year growth rate of 16.99%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ZLAB have?

    As of the end of the reporting period, Zai lab limited (ZLAB) had total debt of 224.26M, with a debt ratio of 0.19. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ZLAB have?

    At the end of the period, Zai lab limited (ZLAB) held Total Cash and Cash Equivalents of 779.57M, accounting for 0.66 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ZLAB go with three margins increasing?

    In the latest report, Zai lab limited (ZLAB) did not achieve the “three margins increasing” benchmark, with a gross margin of 51.2%%, operating margin of -54.01%%, and net margin of -39.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZLAB's profit trajectory and future growth potential.

  • Is ZLAB's EPS continuing to grow?

    According to the past four quarterly reports, Zai lab limited (ZLAB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZLAB?

    Zai lab limited (ZLAB)'s Free Cash Flow (FCF) for the period is -26.7M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 54.26% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ZLAB?

    The latest valuation data shows Zai lab limited (ZLAB) has a Price-To-Earnings (PE) ratio of -12.41 and a Price/Earnings-To-Growth (PEG) ratio of -0.27. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.